In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGI Pharma Inc.

Division of Eisai Co. Ltd.
www.mgipharma.com

Latest From MGI Pharma Inc.

Eisai Joins PROTAC Club Through New Oncology Collab

Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.

Cancer Platform Technologies

Eisai's New Venture Fund Looks To ‘Excavate’ Innovation

Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.

Japan Financing

Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes

America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.

Legal Issues Intellectual Property

Brand Vs. Generic Supreme Court Fight: Does Sale Of Secret Invention Bar Its Patenting?

In case with potentially broad ramifications for biopharma partnerships, high court will hear arguments Dec. 4 on whether America Invents Act changed the "on-sale bar" to patentability to allow inventions that are sold to be patented if their details are not publicly disclosed.

Legal Issues Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register